Article Text

Download PDFPDF
Bifidobacteria and subsets of dendritic cells: friendly players in immune regulation!
  1. Corinne Grangette
  1. Correspondence to Dr Corinne Grangette, Lactic Acid Bacteria and Mucosal Immunity, Center for Infection and Immunity of Lille, INSERM U1019 - CNRS UMR 8204, Institut Pasteur of Lille, 1 rue du Pr Calmette, F59019 Lille Cedex, 59000 Lille, France; corinne.grangette{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The mammalian gastrointestinal tract harbours a vast number of bacterial residents, recently referred to as the microbiota, which are instrumental in supporting energy metabolism and immune function of the host. A large number of studies have highlighted the fact that certain (pathogenic) micro-organisms can be harmful to the health of their host, while more recently an increasing number of papers have attributed direct beneficial health effects to the gut microbial community. As these bacteria encode 100 times more genes than present in the human genome, the partnership of the host with its microbiota constitute a ‘superorganism’.1 Homoeostasis in this superorganism is sustained through an optimal cohabitation of the host with this microbiota, keeping the balance between commensals and pathogens, but also between proinflammatory and regulatory responses. The composition of the gut microbiota has indeed been shown to be an important determinant of Th17:Treg balance and may thus influence intestinal immunity and tolerance.2 Disturbing alterations in the composition of the microbiota (a process known as dysbiosis) will compromise such homoeostasis and promote the development of various inflammatory disorders, such as inflammatory bowel disease. An in-depth understanding of the mechanisms underlying host–symbiont relationships will be pivotal for the development of new therapeutic or prophylactic interventions targeting the intestinal microbiota.

One such approach is the use of probiotics, mainly lactobacilli and bifidobacteria, to impact on …

View Full Text


  • Linked article 300936.

  • Funding CG is supported by the Institut Pasteur of Lille, by l'Association François Aupetit and by INSERM.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles